# A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer

> **NCT00422097** · PHASE1 · COMPLETED · sponsor: **R-Pharm** · enrollment: 40 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** Ixabepilone, 5 mg/d
- **DRUG:** Ixabepilone, 10 mg/d
- **DRUG:** Ixabepilone, 15 mg/d
- **DRUG:** Ixabepilone, 20 mg/d
- **DRUG:** Ixabepilone, 25 mg/d
- **DRUG:** Ixabepilone, 30 mg/d
- **DRUG:** Ixabepilone, 25 mg, with famotidine
- **DRUG:** Ixabepilone, 25 mg, with food

## Key facts

- **NCT ID:** NCT00422097
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2009-08
- **Final completion:** 2011-04
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2016-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00422097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00422097, "A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00422097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*